Molly White currently serves as Vice President of Strategic Initiatives at Dyne Therapeutics, a clinical-stage company focused on genetically driven muscle.
Molly White currently serves as Vice President of Strategic Initiatives at Dyne Therapeutics, a clinical-stage company focused on genetically driven muscle diseases, having joined the firm in 2024. Her work supports the company's strategic efforts in advancing therapeutics for conditions like Duchenne muscular dystrophy and FSHD. She is not a founder of the company.
Full founder directory · Investor directory · Company funding database · Fundraising library